marketshareAI

Solvonis Therapeutics

SVNSIndustrials
0.2480GBX
3.33%
Market Cap
19.80M
Volume
245.91M
457% of avg
P/E Ratio
EPS (TTM)
Beta
1.54
Day Range
0.2300p - 0.2900p
52 Week Range
0.1000p0.2480p0.4700p
0.2480p

Upcoming Events

July 2025
In-vitro screening for SERT, DAT and NET release expected to complete
Q3 2025
Lead candidate selection expected
High Impact Event
Q2 2025
Proposed acquisition of Awakn Life Sciences Corp. expected to complete
High Impact Event
Q1 2026
Phase 2b Trial Initiation for AWKN-002
High Impact Event
Late 2026
Completion of SVNS-001 Phase 3 clinical trial
High Impact Event
Early 2027
Potential regulatory approval for SVNS-001
High Impact Event
SVNS
NEUTRAL

Solvonis Therapeutics Provides AGM Update

The biopharmaceutical company provides an update on its recent Annual General Meeting, highlighting shareholder support and the company's strategic positioning following a key acquisition.

SVNS
NEUTRAL

Solvonis Therapeutics Announces Director Shareholding Change

The specialty industrial machinery company has announced a change in director shareholdings.

SVNS
NEUTRAL

Solvonis Therapeutics Receives Initiation of Research Coverage

The biopharmaceutical company has received initiation of research coverage from Singer Capital Markets, providing an independent assessment of the business.

SVNS
NEUTRAL

Solvonis Therapeutics Announces Allowance of U.S. Patent for AI-Supported CNS Compounds

The biopharmaceutical company announces the allowance of a U.S. patent covering compounds from its AI-supported CNS discovery programme.

SVNS
NEUTRAL

Solvonis Therapeutics Launches AI-Driven CNS Drug Discovery Programme

The biopharmaceutical company is launching an AI-driven drug discovery programme to accelerate the identification and optimization of high-value development candidates within its CNS compound library.

SVNS
NEUTRAL

Solvonis Therapeutics Provides Update on SVN-SDN-014 Preclinical Program

The biopharmaceutical company provides an update on the progress of its preclinical program for a novel treatment targeting trauma-related mental health conditions.

SVNS
NEUTRAL

Solvonis Therapeutics Announces Annual General Meeting

The biopharmaceutical company has announced the details of its upcoming Annual General Meeting, to be held on 27 June 2025.

SVNS
NEUTRAL

Solvonis Therapeutics Appoints Renowned Neuroscientist as Chief Scientific Officer

The biopharmaceutical company has appointed a leading expert in brain science and psychiatric medicine to its management team as Chief Scientific Officer.

SVNS
NEUTRAL

Solvonis Therapeutics Announces Change in Shareholding

The biotechnology company has announced a change in its shareholding structure.

SVNS
NEUTRAL

Solvonis Therapeutics Announces Director Dealings

The biotechnology company has announced changes to its major shareholdings.